KEYNOTE-427 (Cohort A): Phase II Study of Pembrolizumab Monotherapy for First-line Treatment of Patients With Advanced Clear-Cell Renal Cell Carcinoma

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD Vamsidhar Velcheti, MD Released: September 15, 2021

Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, review key data in genitourinary cancers from the 2021 ASCO Annual Meeting, as reported by Clinical Care Options (CCO)

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: September 7, 2021 Expired: September 6, 2022

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

Download slides on selected studies of combination therapy approaches in solid tumors, from ASCO 2021 as reported by Clinical Care Options (CCO).